Clinical Trial

Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies

Study acronym: DRUID
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
DRUID is a treatment decision support tool combining predictive models and public databases related to multi-gene markers, drug response screens, gene essentiality and clinical status of drugs to provide drug recommendations personalized based on an input genomic profile. We hypothesize that DRUID analysis of patients' somatic mutational profile from NGS diagnostic platform can be used as a treatment decision support tool in patients with refractory cancer without targetable mutations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-30; most recent amendment 2025-07-22.
Status change: Not Yet Recruiting → Recruiting 2023-12-20
Trial Details
NCT Number NCT05719428
Lead Sponsor National University Hospital, Singapore
Collaborators: National University of Singapore
Conditions Solid Organ Malignancies
Enrollment 37 participants
Start Date 2023-08-28
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-25